Technical Analysis for INBX - Inhibrx, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 34.62 | -0.23% | -0.08 |
Earnings due: May 24
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | -0.23% | |
| NR7 | Range Contraction | -0.23% | |
| Narrow Range Bar | Range Contraction | -0.23% | |
| BB Squeeze Ended | Range Expansion | -0.23% | |
| Above Upper BB | Strength | -0.23% | |
| Gapped Up | Strength | -0.23% | |
| Up 3 Days in a Row | Strength | -0.23% | |
| Up 4 Days in a Row | Strength | -0.23% | |
| Upper Bollinger Band Touch | Strength | -0.23% | |
| Bollinger Band Squeeze | Range Contraction | 0.38% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 1 hour ago |
| Gap Down Closed | about 2 hours ago |
| Reversed from Down | about 2 hours ago |
| 50 DMA Support | about 2 hours ago |
| Gap Down Partially Closed | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 05/24/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.79 |
| 52 Week Low | 14.305 |
| Average Volume | 484,458 |
| 200-Day Moving Average | 27.87 |
| 50-Day Moving Average | 34.66 |
| 20-Day Moving Average | 34.26 |
| 10-Day Moving Average | 34.39 |
| Average True Range | 0.43 |
| RSI (14) | 54.75 |
| ADX | 18.23 |
| +DI | 15.87 |
| -DI | 14.79 |
| Chandelier Exit (Long, 3 ATRs) | 33.54 |
| Chandelier Exit (Short, 3 ATRs) | 35.01 |
| Upper Bollinger Bands | 34.67 |
| Lower Bollinger Band | 33.86 |
| Percent B (%b) | 1.04 |
| BandWidth | 2.36 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.16 |
| MACD Histogram | 0.08 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 35.02 | ||||
| Resistance 3 (R3) | 34.99 | 34.86 | 34.96 | ||
| Resistance 2 (R2) | 34.86 | 34.78 | 34.87 | 34.94 | |
| Resistance 1 (R1) | 34.78 | 34.73 | 34.82 | 34.81 | 34.93 |
| Pivot Point | 34.65 | 34.65 | 34.67 | 34.66 | 34.65 |
| Support 1 (S1) | 34.57 | 34.57 | 34.61 | 34.60 | 34.47 |
| Support 2 (S2) | 34.44 | 34.52 | 34.45 | 34.46 | |
| Support 3 (S3) | 34.36 | 34.44 | 34.44 | ||
| Support 4 (S4) | 34.39 |
